GB916803A - Vaccine for the protection of humans against trachoma - Google Patents

Vaccine for the protection of humans against trachoma

Info

Publication number
GB916803A
GB916803A GB2617/59A GB261759A GB916803A GB 916803 A GB916803 A GB 916803A GB 2617/59 A GB2617/59 A GB 2617/59A GB 261759 A GB261759 A GB 261759A GB 916803 A GB916803 A GB 916803A
Authority
GB
United Kingdom
Prior art keywords
virus
phosphate buffered
buffered saline
attenuated
embryos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2617/59A
Inventor
Leslie Harold Collier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Development Corp UK
Original Assignee
National Research Development Corp UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Development Corp UK filed Critical National Research Development Corp UK
Priority to GB2617/59A priority Critical patent/GB916803A/en
Publication of GB916803A publication Critical patent/GB916803A/en
Priority to OA50936A priority patent/OA00849A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A vaccine for protection of humans against trachoma comprises purified virulent or attenuated living trachoma virus or inclusion blennorrhoea virus and an injectable pharmaceutical carrier or diluent. The attenuated virus is obtained by many passages through a host such as thick embryos, tissue cultures and animal hosts. It is preferred to cultivate the virulent or attenuated virus in thick embryos which are 6 to 8 days old at inoculation. The embryos are inoculated via the yolk sac with a suspension in saline of yolk sac infected with the virus and containing streptomycin to prevent bacterial infection and are incubated at 35 DEG C. until the yolk sac is rich in virus, any eggs dying within 72 hours of inoculation being rejected. Infected yolk sacs free from bacteria are homogenized with phosphate buffered saline and centrifuged at 200 G for 5 minutes to remove impurities. The supernatant is mixed with more phosphate buffered saline and centrifuged at 40 DEG C. and 12,000 G to deposit the virus. The process is repeated on the deposited virus to bring about further purification. The virus is resuspended in phosphate buffered saline and mixed with sterile aqueous gelatine to give a final concentration of 10% aqueous gelatine. When required for use, the freeze dried product is reconstituted with sterile pyrogen free water. The gelatin is used to inhibit denaturation of the virus during freeze drying and may be replaced by dextran. Specification 764,718 is referred to.
GB2617/59A 1959-01-23 1959-01-23 Vaccine for the protection of humans against trachoma Expired GB916803A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB2617/59A GB916803A (en) 1959-01-23 1959-01-23 Vaccine for the protection of humans against trachoma
OA50936A OA00849A (en) 1959-01-23 1964-12-19 A method of preparing a vaccine against trachoma.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2617/59A GB916803A (en) 1959-01-23 1959-01-23 Vaccine for the protection of humans against trachoma

Publications (1)

Publication Number Publication Date
GB916803A true GB916803A (en) 1963-01-30

Family

ID=9742717

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2617/59A Expired GB916803A (en) 1959-01-23 1959-01-23 Vaccine for the protection of humans against trachoma

Country Status (2)

Country Link
GB (1) GB916803A (en)
OA (1) OA00849A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328208A (en) * 1981-05-20 1982-05-04 Kurbanov Ildus A Vaccine against chlamydous infections of farm animals

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328208A (en) * 1981-05-20 1982-05-04 Kurbanov Ildus A Vaccine against chlamydous infections of farm animals

Also Published As

Publication number Publication date
OA00849A (en) 1967-11-15

Similar Documents

Publication Publication Date Title
Bovarnick et al. The influence of certain salts, amino acids, sugars, and proteins on the stability of rickettsiae
Anjum Experimental transmission of hydropericardium syndrome and protection against it in commercial broiler chickens
Herrell et al. Experimental and clinical studies on gramicidin
Simpson et al. Japanese encephalitis in Sarawak: virus isolation and serology in a Land Dyak village
Borden et al. The interferon refractory state: in vivo and in vitro studies of its mechanism
Shope An antiviral substance from Penicillium funiculosum: II. Effect of helenine upon infection in mice with Semliki Forest virus
Cooper et al. An effect of the graft-versus-host reaction on resistance to experimental bacteraemia
Haas et al. Protective effect of pyocin against lethal Pseudomonas aeruginosa infections in mice
US4322404A (en) Process for the production of new mutants of herpes simplex virus type 1 and type 2
GB916803A (en) Vaccine for the protection of humans against trachoma
EP0256792B1 (en) Vaccines for fowl colibacillosis
Takemoto et al. Influence of acid polysaccharides on plaque formation by influenza A2 and B viruses
Green et al. Protection of embryonated eggs infected with infectious bronchitis or Newcastle disease virus by polypeptides.
Holden The nature and properties of the virus of herpes
Pieroni et al. Endotoxin-Induced Hypersensitivity to Histamine in Mice I. Contrasting Effects of Bacterial Lipopolysaccharides and the Classical Histamine-Sensitizing Factor of Bordetella pertussis
Fisher Experimental Staphylococcal Infection of the Subcutaneous Tissue of the Mouse: II. Promotion of the Infection with Staphylococcal Cells and Products
Hoffstadt et al. A study of the IA and OA strains of the Shope fibroma virus with special reference to the Berry transformation
Findlay et al. Experiments on the growth in vitro of the virus of yellow fever
Miller et al. Protection of mice against lethal action of gonococcal endotoxin by penicillin.
Lukáš et al. A virus inhibitor circulating in the blood of chickens, induced by Francisella tularensis and Listeria monocytogenes
GB806949A (en) Production of pharmaceutical preparations
US3836648A (en) Treatment of canine distemper with a microbial product derived from the bacterium achromobacter stenohalis
Smith Propagation of rabbit fibroma virus in the embryonated egg.
Rose et al. Effect of penicillin and streptomycin on bacterial contamination of chick embryos inoculated with unfiltered sputums
Verlinde et al. Studies on haemagglutination by the EMC-MM-Columbia SK-group of viruses: IV. Experiments with egg-adapted virus